vs
John Marshall Bancorp, Inc.（JMSB）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是John Marshall Bancorp, Inc.的1.8倍（$30.3M vs $16.8M），John Marshall Bancorp, Inc.净利率更高（36.3% vs -221.3%，领先257.7%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 15.3%）
约翰·马歇尔银行控股公司是一家总部位于美国的银行控股企业，通过旗下全资子公司约翰·马歇尔银行开展业务，提供商业及零售银行服务，包括存款、商业贷款、住房抵押贷款等，主要服务美国大西洋中部地区的零售客户和中小微企业。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
JMSB vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.8倍
$16.8M
净利率更高
JMSB
高出257.7%
-221.3%
两年增速更快
RGNX
近两年复合增速
15.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.8M | $30.3M |
| 净利润 | $6.1M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 36.3% | -221.3% |
| 营收同比 | — | 43.0% |
| 净利润同比 | 26.8% | -31.2% |
| 每股收益（稀释后） | $0.43 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JMSBRGNX
| Q1 26 | $16.8M | — | ||
| Q4 25 | $16.4M | $30.3M | ||
| Q3 25 | $16.3M | $29.7M | ||
| Q2 25 | $15.4M | $21.4M | ||
| Q1 25 | $14.6M | $89.0M | ||
| Q4 24 | $14.3M | $21.2M | ||
| Q3 24 | $13.8M | $24.2M | ||
| Q2 24 | $12.6M | $22.3M |
净利润JMSBRGNX
| Q1 26 | $6.1M | — | ||
| Q4 25 | $5.9M | $-67.1M | ||
| Q3 25 | $5.4M | $-61.9M | ||
| Q2 25 | $5.1M | $-70.9M | ||
| Q1 25 | $4.8M | $6.1M | ||
| Q4 24 | $4.8M | $-51.2M | ||
| Q3 24 | $4.2M | $-59.6M | ||
| Q2 24 | $3.9M | $-53.0M |
毛利率JMSBRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% |
营业利润率JMSBRGNX
| Q1 26 | — | — | ||
| Q4 25 | 47.4% | -190.0% | ||
| Q3 25 | 42.2% | -176.3% | ||
| Q2 25 | 42.7% | -296.3% | ||
| Q1 25 | 42.4% | 13.6% | ||
| Q4 24 | 42.5% | -242.1% | ||
| Q3 24 | 38.8% | -256.6% | ||
| Q2 24 | 39.7% | -251.3% |
净利率JMSBRGNX
| Q1 26 | 36.3% | — | ||
| Q4 25 | 36.2% | -221.3% | ||
| Q3 25 | 33.2% | -208.3% | ||
| Q2 25 | 33.1% | -331.8% | ||
| Q1 25 | 32.9% | 6.8% | ||
| Q4 24 | 33.3% | -241.3% | ||
| Q3 24 | 30.7% | -246.3% | ||
| Q2 24 | 30.9% | -237.7% |
每股收益（稀释后）JMSBRGNX
| Q1 26 | $0.43 | — | ||
| Q4 25 | $0.41 | $-1.30 | ||
| Q3 25 | $0.38 | $-1.20 | ||
| Q2 25 | $0.36 | $-1.38 | ||
| Q1 25 | $0.34 | $0.12 | ||
| Q4 24 | $0.33 | $-0.99 | ||
| Q3 24 | $0.30 | $-1.17 | ||
| Q2 24 | $0.27 | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $150.2M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $268.1M | $102.7M |
| 总资产 | $2.4B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资JMSBRGNX
| Q1 26 | $150.2M | — | ||
| Q4 25 | $130.0M | $230.1M | ||
| Q3 25 | $163.6M | $274.2M | ||
| Q2 25 | $116.9M | $323.3M | ||
| Q1 25 | $169.1M | $267.9M | ||
| Q4 24 | $122.5M | $234.7M | ||
| Q3 24 | $177.2M | $255.5M | ||
| Q2 24 | $182.6M | $290.4M |
总债务JMSBRGNX
| Q1 26 | — | — | ||
| Q4 25 | $80.9M | — | ||
| Q3 25 | $80.9M | — | ||
| Q2 25 | $80.8M | — | ||
| Q1 25 | $80.8M | — | ||
| Q4 24 | $80.8M | — | ||
| Q3 24 | $80.8M | — | ||
| Q2 24 | $24.7M | — |
股东权益JMSBRGNX
| Q1 26 | $268.1M | — | ||
| Q4 25 | $265.6M | $102.7M | ||
| Q3 25 | $259.7M | $161.5M | ||
| Q2 25 | $253.7M | $213.7M | ||
| Q1 25 | $253.0M | $274.2M | ||
| Q4 24 | $246.6M | $259.7M | ||
| Q3 24 | $243.1M | $301.4M | ||
| Q2 24 | $235.3M | $348.3M |
总资产JMSBRGNX
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.3B | $453.0M | ||
| Q3 25 | $2.3B | $525.2M | ||
| Q2 25 | $2.3B | $581.0M | ||
| Q1 25 | $2.3B | $490.9M | ||
| Q4 24 | $2.2B | $466.0M | ||
| Q3 24 | $2.3B | $519.1M | ||
| Q2 24 | $2.3B | $569.4M |
负债/权益比JMSBRGNX
| Q1 26 | — | — | ||
| Q4 25 | 0.30× | — | ||
| Q3 25 | 0.31× | — | ||
| Q2 25 | 0.32× | — | ||
| Q1 25 | 0.32× | — | ||
| Q4 24 | 0.33× | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.11× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流JMSBRGNX
| Q1 26 | — | — | ||
| Q4 25 | $22.6M | $-52.3M | ||
| Q3 25 | $1.2M | $-56.0M | ||
| Q2 25 | $7.5M | $-49.3M | ||
| Q1 25 | $7.0M | $33.6M | ||
| Q4 24 | $17.3M | $-31.6M | ||
| Q3 24 | $1.4M | $-40.5M | ||
| Q2 24 | $10.2M | $-45.5M |
自由现金流JMSBRGNX
| Q1 26 | — | — | ||
| Q4 25 | $22.0M | $-52.8M | ||
| Q3 25 | $1.2M | $-56.5M | ||
| Q2 25 | $7.4M | $-49.7M | ||
| Q1 25 | $6.6M | $32.6M | ||
| Q4 24 | $16.8M | $-32.7M | ||
| Q3 24 | $1.3M | $-40.9M | ||
| Q2 24 | $10.1M | $-46.0M |
自由现金流率JMSBRGNX
| Q1 26 | — | — | ||
| Q4 25 | 134.7% | -174.0% | ||
| Q3 25 | 7.3% | -189.9% | ||
| Q2 25 | 47.8% | -232.8% | ||
| Q1 25 | 45.3% | 36.6% | ||
| Q4 24 | 116.9% | -154.2% | ||
| Q3 24 | 9.5% | -168.9% | ||
| Q2 24 | 80.1% | -206.2% |
资本支出强度JMSBRGNX
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 1.7% | ||
| Q3 25 | 0.2% | 1.7% | ||
| Q2 25 | 1.0% | 1.8% | ||
| Q1 25 | 2.3% | 1.2% | ||
| Q4 24 | 3.4% | 5.1% | ||
| Q3 24 | 0.8% | 1.3% | ||
| Q2 24 | 0.4% | 2.1% |
现金转化率JMSBRGNX
| Q1 26 | — | — | ||
| Q4 25 | 3.82× | — | ||
| Q3 25 | 0.23× | — | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 1.45× | 5.53× | ||
| Q4 24 | 3.61× | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 2.60× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JMSB
| Net Interest Income | $16.5M | 98% |
| Noninterest Income | $284.0K | 2% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
